Are the Current Attempts at Standardization of Antiphospholipid Antibodies Still Useful? Emerging Technologies Signal a Shift in Direction

 

 Buy Article Permissions and Reprints

ABSTRACT

The pathogenic role of antiphospholipid antibodies (aPL) has been widely established over past years in several experimental models and clinical studies. Accordingly, the detection of aPL by immunoassays (anticardiolipin antibodies; anti-β2 glycoprotein I antibodies) has become a routine practice in the clinical workup of patients with systemic autoimmune diseases. aPL are mostly assayed using commercial ELISA kits, whose performance has not been found to be sufficiently concordant among the different manufacturers. In the past years, collaborative groups have spent considerable effort to reach some form of standardization but this process is still ongoing. Such lack of standardization has recently become even more crucial, as manufacturers have had to face an increasing demand for fully automated tests for aPL, like those test systems that have been developed for other autoantibodies (e.g., antinuclear antibodies, anti-ENA antibodies). We therefore report our recent experience with two newly developed automated methods for anticardiolipin antibodies testing. In particular, we discuss the results obtained using routine samples, as we believe that these better reflect the “real-life” situation in which those automated methods will operate. We also mention other emerging technologies in the field of aPL detection.

REFERENCES

• 1 Laurell A B, Nilsson I M. Hypergamma-globulinemia, circulating anticoagulant and biologic false positive Wassermann reaction: a study of 2 cases.  J Lab Clin Med. 1957;  49 694-707
  PubMedGoogle Scholar
• 2 Loizou S, Mc Crea J D, Rudge A C et al.. Measurement of anticardiolipin antibodies by an enzyme linked immunosorbent assay (ELISA): standardization and quantitation of results.  Clin Exp Immunol. 1985;  62 738-745
  PubMedGoogle Scholar
• 3 Miyakis S, Lockshin M D, Atsumi T et al.. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).  J Thromb Haemost. 2006;  4 295-306
  CrossrefPubMedGoogle Scholar
• 4 Tincani A, Allegri F, Balestrieri G et al.. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies.  Thromb Res. 2004;  114 553-558
  CrossrefPubMedGoogle Scholar
• 5 Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa M C. Proposals for the measurement of anti-beta2-glycoprotein I antibodies. Standardization group of the European Forum on Antiphospholipid Antibodies.  J Thromb Haemost. 2004;  2 1860-1862
  CrossrefPubMedGoogle Scholar
• 6 Tincani A, Allegri F, Sanmarco M et al.. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determination – an operative project of the European Antiphospholipid Forum.  Thromb Haemost. 2001;  86 575-583
  PubMedGoogle Scholar
• 7 Balestrieri G, Tincani A, Spatola L et al.. Anti-beta2glycoprotein I antibodies. A marker of antiphospholipid syndrome?.  Lupus. 1995;  4 122-130
  CrossrefPubMedGoogle Scholar
• 8 Capuano F, Grasso V, Belforte L et al.. Development of automated assays for anticardiolipin antibodies determination: addressing antigen and standardization issues.  Ann N Y Acad Sci. 2007;  1109 493-502
  CrossrefPubMedGoogle Scholar
• 9 Iverson G M, von Mühlen C A, Staub H L, Lassen A J, Binder W, Norman G L. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI.  J Autoimmun. 2006;  27 266-271
  CrossrefPubMedGoogle Scholar
• 10 de Laat B, Derksen R H, Urbanus R T, de Groot P G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis.  Blood. 2005;  105 1540-1545
  CrossrefPubMedGoogle Scholar
• 11 de Laat B, Wu X X, van Lummel M, Derksen R H, de Groot P G, Rand J H. Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin A5.  Blood. 2007;  109 1490-1494
  CrossrefPubMedGoogle Scholar
• 12 Favaloro E J, Wong R C, Silvestrini R, McEvoy R, Jovanovich S, Roberts-Thomson P. A multilaboratory peer assessment quality assurance program-based evaluation of anticardiolipin antibody, and beta2-glycoprotein I antibody testing.  Semin Thromb Hemost. 2005;  31 73-84
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Sanmarco M, Bardin N, Blank M et al.. Heterogenity for anti-beta2-glycoprotein I antibodies. A factor of variability in test results.  Thromb Haemost. 2005;  93 80-87
  PubMedGoogle Scholar
• 14 Reber G, Tincani A, Sanmarco M, de Moerloose P, Boffa M C. European Forum on Antiphospholipid Antibodies Standardization Group . Variability of anti-beta2 glycoprotein I antibodies measurement by commercial assays.  Thromb Haemost. 2005;  94 665-672
  PubMedGoogle Scholar
• 15 Cavazzana A, Ruffatti A, Tonello M, Bortolati M, De Moerloose P, Reber G. An analysis of experimental conditions influencing the anti-beta2-glycoprotein I ELISA assay results.  Ann N Y Acad Sci. 2007;  1109 484-492
  CrossrefPubMedGoogle Scholar

Angela TincaniM.D. 

Associate Professor of Rheumatology, Spedali Civili and University of Brescia

Piazzale Spedali Civili, 1, 25123 Brescia, Italy

Email: tincani@bresciareumatologia.it